18-Oct-2026 10:04:12
BAJAJ HEALTHCAREAcquisition and merger
BAJAJ HEALTHCARE Q2 FY27: STRONG GROWTH, FORMULATIONS UP 82% YOY š¢
ā¢ FORMULATIONS REVENUE UP 82% YOY; API EXPORTS UP 28.5% YOY. ā¢ API EXPORTS + FORMULATIONS COMBINED REVENUE CROSSED ā¹100 CR IN Q2. ā¢ GENRX ACQUISITION: RECEIVED NCLT APPROVAL TO EXPAND FORMULATION CAPABILITIES. ā¢ CENOBAMATE: FIRST INDIAN COMPANY TO RECEIVE DCGI APPROVAL FOR API AND TABLETS. ā¢ PEPTIDE FACILITY: COMMISSIONING ON TRACK FOR Q4 FY27.
BAJAJ HEALTHCARE LIMITED